Senti Biosciences Holdings, Inc.

Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies. The company engineers these therapies using its proprietary gene circuit platform technologies, aiming to treat patients with incurable diseases. Senti's synthetic biology platform programs cell and gene therapies with gene circuits, which are novel combinations of DNA sequences. These gene circuits are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to their cellular environments. This allows product candidates to precisely kill cancer cells, spare healthy cells, increase specificity to target cells, and control drug expression post-administration. Senti applies its gene circuit technologies to develop medicines using chimeric antigen receptor (CAR) white blood cells, specifically focusing on oncology. The company's lead product candidates utilize off-the-shelf healthy adult donor-derived natural killer (NK) cells to create CAR-NK cells equipped with gene circuit technologies for various oncology indications with high unmet need. Senti's lead product candidate, SENTI-202, is a Logic Gated off-the-shelf CAR-NK cell therapy for blood cancers. It is currently being studied in an open-label, multi-center Phase 1 clinical trial in the United States and Australia for relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia (AML). The company's pipeline also includes preclinical programs, such as a solid tumor cell therapy program and partnered programs with BlueRock Therapeutics, Inc. for cell therapies in regenerative medicines. SENTI-202 is the most advanced program and originated from Senti's internal pipeline.